Zensar Technologies Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9rlzv5pispnbu0vn7ep2rm3e.pdf

Key Takeaways


The Profit-First Posture

Manish Tandon: "I'm a bit old school. I still focus on the bottom line... I will not go in for revenues that don't lead to profitability and margins."

Margin Walk & Sustainability

Margin driver (QoQ)ImpactDurability
Positive forex+0.7%Variable
Improved offshore effort mix+1.4%Structural, likely to stay
Leave utilization benefit+1.0%One-off, reverses next quarter
Other operational efficiencies+0.7%Partially one-off
Furlough impact–1.0%Seasonal
Full-quarter ESOP cost–0.9%Recurring
Net EBITDA expansion+200 bps

Vertical Health Check

VerticalTrendCommentary
BFSI▲ Secular growthStrength across Europe, Africa and US; broad-based demand.
TMT▼ Structural dragNow less than 10% of revenue; large clients spending on capex/hardware not services, in-sourcing underway, ~30% discounts given to retain business. Management's guess is "on the downside than on the upside."
Life Sciences & Healthcare▼ Consolidation hitOn the wrong end of consolidation in 1–2 accounts; some Q4 impact expected but not material at company level.
Manufacturing / Consumer Services▬ Green shootsPrimarily retail exposure; some early positive signals but limited scale.
Manish Tandon: "My challenge now to myself and the team is that can we deliver double-digit growth despite TMT not delivering."

AI: Conservative Classification, Early Build-Out

Manish Tandon: "I don't want this to treat AI like people used to treat digital, but suddenly 100% of their revenues became digital overnight. So, I don't want to do that."

The Transformation Context

Manish Tandon: "What we inherited was really a slightly more advanced form of a staff augmentation company, to be very frank."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginMaintain mid-teen margin; some improvements sustain but endeavour is to invest back into AI and salesOngoing
Double-digit profit growthCommitted to delivering double-digit profit growth going forwardNo date
TMT decouplingDeliver double-digit company growth despite TMT staying flat at bestNo date
Volume-to-revenue conversionIf volume growth sustains with higher working days, revenue should start reflecting itQ4 FY26 (conditional)
Life Sciences headwindSome impact expected in Q4 but not material at company levelQ4 FY26
M&AActively evaluating inorganic opportunities, accretive to revenue and bottom lineNo date

Key Metrics

MetricQ3 FY26
Revenue (USD)$160.5 million, +2.2% YoY reported, +1.3% YoY constant currency, -1.4% QoQ reported
Revenue (INR)+7.9% YoY, +0.7% QoQ
Gross profit33.7%, +270 bps QoQ
EBITDA17.4%, +200 bps QoQ
PAT13.9%, includes INR 25 crore impact from new labour code changes
Diluted EPSINR 8.7 per share, +9.4% QoQ
Profit growth (USD)+18.2% YoY
EPS growth+24.1% YoY
Order book$180.2 million, +13.6% QoQ, book-to-bill 1.12x
Net cash and cash equivalents$322.4 million, +29.4 million QoQ
DSO71 days
Interim dividendINR 2.4 per share, 120% of face value
Utilization83.5%, +60 bps YoY, -130 bps QoQ
Voluntary attrition9.5%, fourth successive quarter below 10%
Gross employee addition988 employees
Volume growth1.7% overall, offshore 3.1%, on-site declined
Service lines share of revenue69%, +220 bps YoY
AI-influenced order book20% of new order book (EN and NN only)
BFSI revenue growth (YoY reported)+12.2%
Healthcare and Life Sciences revenue growth (YoY reported)+5.2%
Manufacturing and Consumer Services revenue growth (YoY reported)-2.7%
TMT revenue growth (YoY reported)-11.6%
Cloud Infrastructure and Security services growth (YoY reported)+10.9%
Data Engineering and Analytics growth (YoY reported)+13.1%
Enterprise Application services growth (YoY reported)-3.6%